150 related articles for article (PubMed ID: 23902131)
1. Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia.
Swartz TH; Huprikar S; Labombardi V; Pinney S; Anyanwu A; Lee M; Patel G
Transpl Infect Dis; 2013 Oct; 15(5):E177-81. PubMed ID: 23902131
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.
Marcos LA; Camins BC
Antimicrob Agents Chemother; 2010 Dec; 54(12):5376-8. PubMed ID: 20876369
[TBL] [Abstract][Full Text] [Related]
3. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
4. Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus.
Fusco DN; Alexander EL; Weisenberg SA; Mediavilla JR; Kreiswirth BN; Schuetz AN; Jenkins SG; Rhee KY
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):180-3. PubMed ID: 19748429
[TBL] [Abstract][Full Text] [Related]
5. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
[TBL] [Abstract][Full Text] [Related]
6. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
7. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
8. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
[TBL] [Abstract][Full Text] [Related]
9. A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i.
Chaiwongkarjohn S; Pramyothin P; Suwantarat N; Bankowski MJ; Koyamatsu T; Seifried SE; Bello EF
Hawaii Med J; 2011 Nov; 70(11):233-6. PubMed ID: 22162601
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
Fong RK; Low J; Koh TH; Kurup A
Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):983-7. PubMed ID: 19387707
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
Gomes DM; Ward KE; LaPlante KL
Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.
Price J; Atkinson S; Llewelyn M; Paul J
Clin Infect Dis; 2009 Apr; 48(7):997-8. PubMed ID: 19260820
[No Abstract] [Full Text] [Related]
17. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Crandon JL; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
[TBL] [Abstract][Full Text] [Related]
18. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models.
Smith K; Gemmell CG; Lang S
Eur J Clin Microbiol Infect Dis; 2013 Oct; 32(10):1327-32. PubMed ID: 23624635
[TBL] [Abstract][Full Text] [Related]
19. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
20. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Leonard SN; Supple ME; Gandhi RG; Patel MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
